Literature DB >> 20476668

Markers of degeneration and regeneration in Duchenne muscular dystrophy.

E Abdel-Salam1, I Abdel-Meguid, S S Korraa.   

Abstract

Dystrophin deficiency associated with Duchenne muscular dystrophy (DMD) results in chronic inflammation and severe skeletal muscle degeneration, where the extent of muscle fibrosis contributes to disease severity. The microenvironment of dystrophic muscles is associated with variation in levels of markers of degeneration and regeneration. Since in dystrophic muscle apoptosis precedes necrosis, markers of apoptosis can be used as indicators of degeneration, while regeneration can be measured in terms of cytokines and growth factor expression"; and then throughout the text use "markers of apoptosis/degeneration. The present study is an attempt to evaluate the extent of degeneration and regeneration in DMD patient blood. Subjects were 24 boys with DMD diagnosed at the molecular level versus 20 age and socioeconomic matching healthy boys. In their blood, levels of Fas and FasL and Bax/Bcl-2 and plasma DNA fragmentation were measured as markers of apoptosis. The cytokine tumor necrosis factor alfa (TNF-alpha), and the growth factors: basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) were measured as markers of regeneration. Plasma DNA fragmentation (0.38% +/- 0.12 vs. 0.2% +/- 0.15) and Fas (9.9 +/- 2.8 vs. 2 +/- 0.1, p < 0.001) together with FasL mRNA expression in circulating lymphocytes (0.47 +/- .09 vs. 0.24 +/- .04, p < 0.001) were significantly increased in DMD patients compared to controls. There was a significant increase in Bax (0.19 +/- 0.7 vs. 0.05 +/- 0.1, p < 0.00001) expression and a significant decrease in Bcl-2 protein (6.4 +/- 1.6 vs 10 +/- 2.8, p < 0.00001) as compared to controls. Among markers of regeneration, TNF- alpha (30.2 +/- 9.5 vs. 3.6 +/- 0.9) and bFGF (21.7 +/- 10.3 vs. 4.75 +/- 2.2) were significant increased while VEGF was significantly decreased (190 +/- 115 vs. 210 +/- 142.) in blood of DMD patients compared to controls. Our results indicate that Fas/FasL and Bax/Bcl-2 are involved in muscle atrophy and degeneration in DMD patients, while regeneration process does not cope with the degeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20476668      PMCID: PMC2858946     

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  63 in total

1.  bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship.

Authors:  A Strasser; A W Harris; S Cory
Journal:  Cell       Date:  1991-11-29       Impact factor: 41.582

2.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

Authors:  Z N Oltvai; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

3.  Elevated basic fibroblast growth factor in the serum of patients with Duchenne muscular dystrophy.

Authors:  P A D'Amore; R H Brown; P T Ku; E P Hoffman; H Watanabe; K Arahata; T Ishihara; J Folkman
Journal:  Ann Neurol       Date:  1994-03       Impact factor: 10.422

4.  Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor.

Authors:  Keisuke Kondoh; Hiroyuki Koyama; Tetsuro Miyata; Tsuyoshi Takato; Hirohumi Hamada; Hiroshi Shigematsu
Journal:  Cardiovasc Res       Date:  2004-01-01       Impact factor: 10.787

5.  Angiogenic growth factor response to acute systemic exercise in human skeletal muscle.

Authors:  Timothy P Gavin; Christopher B Robinson; Robert C Yeager; Justin A England; L Wiley Nifong; Robert C Hickner
Journal:  J Appl Physiol (1985)       Date:  2003-08-29

6.  Effects of exercise and steroid on skeletal muscle apoptosis in the mdx mouse.

Authors:  Jeong-Hoon Lim; Dai-Youl Kim; Moon Suk Bang
Journal:  Muscle Nerve       Date:  2004-10       Impact factor: 3.217

7.  Muscle regeneration after imposed injury is better in younger than older mdx dystrophic mice.

Authors:  J M Zacharias; J E Anderson
Journal:  J Neurol Sci       Date:  1991-08       Impact factor: 3.181

8.  Distinctive patterns of basic fibroblast growth factor (bFGF) distribution in degenerating and regenerating areas of dystrophic (mdx) striated muscles.

Authors:  J E Anderson; L Liu; E Kardami
Journal:  Dev Biol       Date:  1991-09       Impact factor: 3.582

Review 9.  Targeting the immune system to improve ventilatory function in muscular dystrophy.

Authors:  Luc E Gosselin; Kathleen M McCormick
Journal:  Med Sci Sports Exerc       Date:  2004-01       Impact factor: 5.411

10.  Longitudinal pathologic study of the gastrocnemius muscle group in mdx mice.

Authors:  Manuel Roig; Josep Roma; Arnau Fargas; Francina Munell
Journal:  Acta Neuropathol       Date:  2003-10-07       Impact factor: 17.088

View more
  18 in total

Review 1.  What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?

Authors:  Jennifer Manning; Dervla O'Malley
Journal:  J Muscle Res Cell Motil       Date:  2015-02-11       Impact factor: 2.698

2.  D-Amino Acid Substitution of Peptide-Mediated NF-κB Suppression in mdx Mice Preserves Therapeutic Benefit in Skeletal Muscle, but Causes Kidney Toxicity.

Authors:  Daniel P Reay; Sheldon I Bastacky; Kathryn E Wack; Donna B Stolz; Paul D Robbins; Paula R Clemens
Journal:  Mol Med       Date:  2015-05-22       Impact factor: 6.354

Review 3.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 4.  Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.

Authors:  Alessandra Govoni; Francesca Magri; Simona Brajkovic; Chiara Zanetta; Irene Faravelli; Stefania Corti; Nereo Bresolin; Giacomo P Comi
Journal:  Cell Mol Life Sci       Date:  2013-06-18       Impact factor: 9.261

5.  Multiple poloxamers increase plasma membrane repair capacity in muscle and nonmuscle cells.

Authors:  Thomas A Kwiatkowski; Aubrey L Rose; Rachel Jung; Ana Capati; Diana Hallak; Rosalie Yan; Noah Weisleder
Journal:  Am J Physiol Cell Physiol       Date:  2019-11-20       Impact factor: 4.249

Review 6.  Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy.

Authors:  Jong-Hee Kim; Hyo-Bum Kwak; LaDora V Thompson; John M Lawler
Journal:  J Muscle Res Cell Motil       Date:  2012-10-28       Impact factor: 2.698

7.  Identification of critical molecular pathways involved in exosome-mediated improvement of cardiac function in a mouse model of muscular dystrophy.

Authors:  Xuan Su; Yan Shen; Yue Jin; Neal L Weintraub; Yao-Liang Tang
Journal:  Acta Pharmacol Sin       Date:  2020-06-29       Impact factor: 6.150

8.  Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy.

Authors:  Ekaterina Kotelnikova; Maria A Shkrob; Mikhail A Pyatnitskiy; Alessandra Ferlini; Nikolai Daraselia
Journal:  PLoS Comput Biol       Date:  2012-02-02       Impact factor: 4.475

Review 9.  Angiogenesis as a novel therapeutic strategy for Duchenne muscular dystrophy through decreased ischemia and increased satellite cells.

Authors:  Yuko Shimizu-Motohashi; Atsushi Asakura
Journal:  Front Physiol       Date:  2014-02-18       Impact factor: 4.566

Review 10.  Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy.

Authors:  Boel De Paepe; Jan L De Bleecker
Journal:  Mediators Inflamm       Date:  2013-11-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.